SABCS 2019: After 6 Years, Adding Pertuzumab to Trastuzumab + Chemotherapy Continues to Yield Clinical Benefit in Operable HER2+ Early Breast Cancer
Six-year data from the APHINITY trial were reported.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.